Under the contract, SRI will carry on with the development of NIAID’s Division of Microbiology and Infectious Diseases (DMID) program that involves translation of basic research into clinical applications.
The award is believed to support preclinical development of drugs in treating various diseases caused by bacteria, fungi, viruses, parasites, toxins, drug-resistant organisms, and bioterrorism agents.
SRI will provide services in four major areas to move potential drugs from early-stage discovery to clinical assessment.
The services include drug discovery support; formulation development, analytical chemistry, and clinical manufacturing; toxicology and pharmacology; and regulatory assessment and product feasibility.